Pulmonx reports record Q2 revenue $20.8M (+21% YoY); net loss narrows to $15.3M

Pulmonx Corp

2024-Q2 EPS reported -$0.75 revenue$39,637,000

Worldwide revenue $20.8M, up 21% YoY; U.S. revenue $13.9M (+26%); International $6.9M (+12%).
Net loss $15.3M ($0.39/share) vs $16.2M ($0.43) in Q2 2023; adjusted EBITDA loss $7.6M vs $10.3M.
Gross margin held at 74%; operating expenses $30.9M, including $1.7M one-time software impairment.
Added 17 new U.S. Zephyr Valve treatment centers; first U.S. patients treated in AeriSeal CONVERT II trial.
Full-year 2024 guidance reaffirmed: revenue $81-84M, gross margin 74-75%, opex $127-129M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.